L&G Pharma Breakthrough UCITS ETF | BIOTRegistrer dig for at låse op for ratings |
Fondens performance | 30-04-2024 |
Vækst af 1.000 (DKK) | Avanceret graf |
Fond | 17,2 | 3,6 | -2,4 | -12,2 | -8,8 | |
+/-Kat | -1,5 | 6,7 | 10,4 | -13,5 | -6,4 | |
+/-Indeks | -8,1 | -3,2 | 0,6 | -22,3 | -16,8 | |
Kategori: Sektor - Bioteknologi, Aktier | ||||||
Kategoribenchmark: Morningstar Gbl Biotechnolo... |
Oversigt | ||
Closing Price 10-05-2024 | USD 9,71 | |
Kursændring 1 dag | -0,12% | |
Morningstar Kategori™ | Sektor - Bioteknologi, Aktier | |
Omsætning | 1827 | |
Børs | LONDON STOCK EXCHANGE, THE | |
ISIN | IE00BF0H7608 | |
Markedsværdi i alt (mio.) 10-05-2024 | USD 18,78 | |
Seneste TNA(mio.) 10-05-2024 | USD 18,78 | |
Løbende omkostning 14-02-2024 | 0,49% | |
Investeringsstrategi | Passiv |
Investeringsmålsætning: L&G Pharma Breakthrough UCITS ETF | BIOT |
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position. |
Returns | |||||||||||||
|
Management | ||
Manager navn Startdato | ||
- - | ||
Startdato 18-01-2018 |
Annonce |
Kategoribenchmark | |
Fondens indeks | Morningstar indeks |
Solactive Pharma Breakthrough V NR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Formuefordeling L&G Pharma Breakthrough UCITS ETF | BIOT | 10-05-2024 |
|
|
Top 5 placeringer | Sektor | % |
SciClone Pharmaceuticals (Holdin... | Healthcare | 3,28 |
AstraZeneca PLC ADR | Healthcare | 2,85 |
Ipsen SA | Healthcare | 2,80 |
United Therapeutics Corp | Healthcare | 2,72 |
Pharma Mar SA | Healthcare | 2,58 |
Øget Mindsket Ny siden sidste portefølje | ||
L&G Pharma Breakthrough UCITS ETF | BIOT |